USSTOCK.TODAY
Regular Market
Log in Sign up

Bristol Myers Squibb shares fall about 4% on Phase 3 lung disease treatment results

BioPharma Dive +1 ·

BMY Bristol-Myers Squibb Co
$58.83 -1.54%
View chart & analysis →
MRK -1.59%
  1. 1Bristol Myers Squibb's experimental lung disease treatment admiralpant succeeded in a Phase 3 trial for idiopathic pulmonary fibrosis.
  2. 2A clear benefit was confirmed in the 60mg dose group, but the 120mg dose group did not meet the criteria for statistical significance.
  3. 3Bristol Myers Squibb shares rose more than 6% in premarket trading before closing down about 4%.

So what's the key point?

Bristol Myers Squibb's lung disease treatment showed some effectiveness in clinical trials. The stock price rose more than 6% before the market opened but ended down about 4%.

Source BioPharma Dive +1 · View original ↗

Related 3-line summaries

Bristol Myers Squibb: High Dividend Yield and Turnaround Expectations The Motley Fool +1 · 3h agoEli Lilly Stock Split Possibility and Corporate Status Nasdaq +2 · Oct 13Bristol Myers Squibb shares surge 6.5% on successful Phase 3 clinical trial results Investing.com +3 · Oct 12
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news